[{"id":"e93a92c7-6866-40c4-a6f7-c638e6fc335c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05774873","created_at":"2023-03-20T20:03:20.451Z","updated_at":"2024-07-02T16:35:27.934Z","phase":"Phase 1/2","brief_title":"IBI334 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT05774873","lead_sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","biomarkers":" RAS","pipe":" | ","alterations":" RAS wild-type","tags":["RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IBI-334"],"overall_status":"Recruiting","enrollment":" Enrollment 128","initiation":"Initiation: 08/09/2023","start_date":" 08/09/2023","primary_txt":" Primary completion: 10/31/2025","primary_completion_date":" 10/31/2025","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2023-11-28"}]